



ASCELIA PHARMA

Share ticker: ACE
Nasdaq Stockholm

www.ascelia.com

[!\[\]\(666e09182d4cd268646ea700ea60dcdf_img.jpg\) Follow us on LinkedIn](#)

ONCORAL CLEAR UNMET MEDICAL NEED

CEO Magnus Corfitzen

January 2021

ASCELIA PHARMA – ADVANCING ORPHAN ONCOLOGY



IMPROVING THE LIFE FOR PEOPLE
WITH RARE ONCOLOGY-RELATED
CONDITIONS

CURRENT ASSETS

Mangoral

- Global Phase 3 development ongoing
- For liver MRI in subset of overall population (Orphan Drug)

Oncoral

- Novel irinotecan tablet ready for Phase 2
- Focus on gastric cancer; potential in other cancer types

CAPABILITIES

People & Partners

- Strong experienced team
- World class network of global KOLs and advisors
- Supply chain in place

Financial

- Fully financed to reach substantial value creating milestones
- Listed on NASDAQ

ONCOLOGY: CONTINUED UNMET NEEDS

UNMET NEEDS IN ONCOLOGY¹

Early diagnosis and intervention

More effective treatment:

- **Improved** therapies (chemo, targeted, immuno, hormonal)
- **Personalized regimens**

Balancing efficacy and clinical outcomes with tolerability

CHEMOTHERAPY: LEADING THERAPY

Prevent the division and growth of cancer cells by killing rapidly dividing cells

Standard of care first line treatment in many solid tumor indications

Combinations common to maximize treatment effect



Sources

1) Ascelia Pharma analysis based on Global Oncology Trends 2019, IQVIA (2018 figures)

ONCORAL – OPTIMIZING EFFICACY AND TOLERABILITY



IRINOTECAN CHEMOTHERAPY

**ESTABLISHED POTENT
ANTI-TUMOR EFFECT**

**– EVEN IN DIFFICULT TO
TREAT CANCERS**

>>

**DAILY
DOSING**



ONCORAL POTENTIAL

**BETTER PATIENT
OUTCOMES
&
IMPROVED
SAFETY**

ONCORAL HAS A STRONG PROFILE IN GASTRIC CANCER

GASTRIC CANCER – A DISEASE WITH POOR OUTCOMES



FREQUENT CAUSE OF DEATH^{1,2}

- 5th most frequent cancer (1 million annual incidence)
- 3rd most frequent cause of cancer death
- 5-year survival ~20%

UNMET NEEDS AND POOR TREATMENT OPTIONS^{1,3}

- Late diagnosis (US and EU)
- Poor outcomes and survival rates
- Poorly defined treatment/combinations for advanced stage
- Need for safer/more tolerable therapy options

CLINICALLY VALIDATED

- Irinotecan approved use in Japan
- Publications and guidelines support use
- Orphan disease in the US and EU


1) Lordick et al. Unmet needs and challenges in gastric cancer: The way forward; Cancer Treatment Reviews 40 (2014) 692–700

2) World Cancer Research Fund International (www.wcrf.org)

3) GlobalData - Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2024

GASTRIC CANCER IS A \$3BN+ MARKET IN NEED OF BETTER TREATMENT OPTIONS

US and EU target patient population



OTHER KEY MARKETS

Japan and South Korea with high prevalence and diagnosis rates (~150,000 diagnosed patients)

China is the country in the world with the highest number of gastric cancer patients (~400,000 diagnosed patients)

...as well as other markets (~400,000 diagnosed patients)

EXPANSION BEYOND GASTRIC CANCER

18M+ new incidences of cancer yearly¹

Broadly demonstrated effect of irinotecan (to date)²

	0	1,000	2,000	% of cases ¹	Examples
Lung				12.3	Clinically demonstrated (non/small cell) & NCCN recognized (small cell)
Colorectal				10.6	Approved indication for 1 st to 3 rd line metastatic
Stomach				6.1	Clinically demonstrated and NCCN recognized (JP/CN approved)
Liver				5.0	Clinically demonstrated
Oesophagus				3.4	Clinically demonstrated and NCCN recognized
Non-Hodgkin...				3.0	Clinically demonstrated
Pancreas				2.7	Approved indication for 1 st to 3 rd line metastatic
Leukemia				2.6	Clinically demonstrated
Kidney				2.4	Clinically demonstrated
Cervical				1.7	Clinically demonstrated and NCCN recognized
Ovarian				1.7	Clinically demonstrated and NCCN recognized
Bone, bile duct, CNS..				Rare	Clinically demonstrated and/or NCCN recognized

Source:

1) <https://www.wcrf.org/dietandcancer/cancer-trends/worldwide-cancer-data>

2) ESMO Clinical Practice Guidelines. ASCO Clinical Practice Guidelines. NCCN Guidelines and www.clinicaltrials.com.

ASCELIA PHARMA: ADVANCING ORPHAN ONCOLOGY

IMPROVING THE LIFE FOR PEOPLE WITH RARE ONCOLOGY-RELATED CONDITIONS

**We develop and
commercialize drugs with:**

MANGORAL –
Advancing liver imaging

ONCORAL –
Advancing chemotherapy

Unmet medical need



Niche/orphan indication



Known mode of action



Clear development & market pathway



Potential for global leadership

